Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Neuropharmacology. 2018 Jun 28;139:26–40. doi: 10.1016/j.neuropharm.2018.06.037

Figure 4. CpG and CH methylation of EGR1 in the mPFC and NAc.

Figure 4

Bisulfite amplicon sequencing (BSAS) was used to assess site-specific methylation in EGR2. (A) Representation of EGR2 gene (promoter and gene body) and BSAS primer placement (1–1, 1–2, 1–3, 1–4, 1–5). (B) Site-specific differences in methylation were observed in within the gene body of EGR1 in the NAc. (C) No site-specific methylation differences were observed in the EGR2 in the mPFC. (D) Higher CH methylation at site 1461 was observed in the NAc of the enriched saline group. (E) No differences in CH methylation were observed in the mPFC. 2-way ANOVA, n=5–10/group.